Welcome to the Clinical Education Center

This Clinical Education Center is intended to provide up-to-date information on topics ranging from product information to recent presentations at congresses to help you become well-informed on all things Qwo®.

This section will not provide product certification – please visit the Ready for QWO page and request to be contacted by an Aesthetic Business Manager for certification information.

Science of Cellulite

Product Information

Publications & Presentations

Clinical Practice

Need More Info?

If you did not find what you are looking for or have a specific Medical Inquiry, click here to access Endo’s Medical Information Portal.

Indication

Qwo® is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

Important Safety Information for QWO

Contraindications

QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

Warnings and Precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions including anaphylaxis have been reported with the use of collagenase clostridium histolyticum. If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

Injection Site Bruising

In clinical trials, 84% of subjects treated with QWO experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking ≤150 mg aspirin daily) were excluded from participating in Trials 1 and 2.

QWO should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet (except those taking ≤150 mg aspirin daily) or anticoagulant therapy.

Substitution of Collagenase Products

QWO must not be substituted with other injectable collagenase products.

QWO is not intended for the treatment of Peyronie’s Disease or Dupuytren’s Contracture.

Adverse Reactions

In clinical trials, the most commonly reported adverse reactions in patients treated with QWO with an incidence ≥ 10% were at the injection site: bruising, pain, nodule and pruritus.

View Full Prescribing Information for QWO.